Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB

In this paper, 58 obese participants were metabolically profiled before and after an 8-week regime of a very low-calorie diet, and over a 1 year follow-up.

In the follow-up, individuals were randomly assigned weight maintenance with meal replacements containing liraglutide (or placebo) for a 1 year period. In the follow-up, lipid profiles of both groups largely returned to their pre-weight loss levels, except for apoB which remained low in the liraglutide group. These results suggest that the apoB-lowering effect of liraglutide may be independent of weight loss.